Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Autor: Leila N. Atmowihardjo, Job R. Schippers, Erik Duijvelaar, Imke H. Bartelink, Pierre M. Bet, Noortje E. L. Swart, Nienke van Rein, Keith Purdy, David Cavalla, Andrew McElroy, Sarah Fritchley, Anton Vonk Noordegraaf, Henrik Endeman, Patricia van Velzen, Matty Koopmans, Harm Jan Bogaard, Leo Heunks, Nicole Juffermans, Marcus J. Schultz, Pieter R. Tuinman, Lieuwe D. J. Bos, Jurjan Aman

Publikováno v: Critical Care, Vol 27, Iss 1, Pp 1-13 (2023)

Abstract Purpose A hallmark of acute respiratory distress syndrome (ARDS) is hypoxaemic respiratory failure due to pulmonary vascular hyperpermeability. The tyrosine kinase inhibitor imatinib reversed pulmonary capillary leak in preclinical studies a

Externí odkaz: https://doaj.org/article/9b66fd0c759d40f6b53c6782c1837294

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Autor: Leila Atmowihardjo, Job R. Schippers, Imke H. Bartelink, Pierre M. Bet, Nienke van Rein, Keith Purdy, David Cavalla, Valérie Comberiati, Andrew McElroy, Sue D. Snape, Harm Jan Bogaard, Leo Heunks, Nicole Juffermans, Marcus Schultz, Pieter R. Tuinman, Lieuwe D. J. Bos, Jurjan Aman

Publikováno v: Trials, Vol 23, Iss 1, Pp 1-17 (2022)

Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical co

Externí odkaz: https://doaj.org/article/27dbdb47d79d4a0092fff3b3856e4135

Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods

Autor: Marieke J. Henstra, Thomas C. Feenstra, Rob M. Kok, Harm-Pieter Spaans, Eric van Exel, Annemiek Dols, Mardien Oudega, Anton C. M. Vergouwen, Adriano van der Loo, Pierre M. Bet, Stephan A. Loer, Merijn Eikelenboom, Pascal Sienaert, Simon Lambrichts, Filip Bouckaert, Judith E. Bosmans, Nathalie van der Velde, Aartjan T. F. Beekman, Max L. Stek, Didi Rhebergen

Publikováno v: Frontiers in Psychiatry, Vol 13 (2022)

BackgroundCognitive side-effects are an important reason for the limited use of electroconvulsive therapy (ECT). Cognitive side-effects are heterogeneous and occur frequently in older persons. To date, insight into these side-effects is hampered due

Externí odkaz: https://doaj.org/article/05849dcdd85d453c8fbb5959a0a507e3

Implementation of a pharmacist-led transitional pharmaceutical care programme

Autor: Selma En‐nasery‐de Heer, Elien B. Uitvlugt, Pierre M. Bet, Bart J. F. van den Bemt, Aida Alai, Patricia M. L. A. van den Bemt, Eleonora L. Swart, Fatma Karapinar‐Çarkit, Jacqueline G. Hugtenburg

Publikováno v: Journal of Clinical Pharmacy and Therapeutics, 47, 7, pp. 1049-1069
Journal of Clinical Pharmacy and Therapeutics, 47(7), 1049-1069. Blackwell Publishing Ltd
en-nasery-de Heer, S, Uitvlugt, E B, Bet, P M, van den Bemt, B J F, Alai, A, van den Bemt, P M L A, Swart, E L, Karapinar-Çarkit, F & Hugtenburg, J G 2022, ' Implementation of a pharmacist-led transitional pharmaceutical care programme : Process evaluation of Medication Actions to Reduce hospital admissions through a collaboration between Community and Hospital pharmacists (MARCH) ', Journal of Clinical Pharmacy and Therapeutics, vol. 47, no. 7, pp. 1049-1069 . https://doi.org/10.1111/jcpt.13645
Journal of Clinical Pharmacy and Therapeutics, 47(7), 1049-1069. Wiley-Blackwell
Journal of Clinical Pharmacy and Therapeutics, 47, 1049-1069

Contains fulltext : 283012.pdf (Publisher’s version ) (Open Access) WHAT IS KNOWN AND OBJECTIVE: The recently conducted Medication Actions to Reduce hospital admissions through a collaboration between Community and Hospital pharmacists (MARCH) tran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b930d2521d2150f6c7d2a737e8018592
https://doi.org/10.1111/jcpt.13645

Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids

Autor: Mei-An Middelkoop, Maria E de Lange, T Justin Clark, Ben Willem J Mol, Pierre M Bet, Judith A F Huirne, Wouter J K Hehenkamp

Publikováno v: Middelkoop, M-A, de Lange, M E, Clark, T J, Mol, B W J, Bet, P M, Huirne, J A F & Hehenkamp, W J K 2022, ' Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids ', Human reproduction (Oxford, England), vol. 37, no. 5, pp. 884-894 . https://doi.org/10.1093/humrep/deac009

Ulipristal acetate (UPA) is a medical treatment for uterine fibroids and was authorized for surgical pre-treatment in 2012 after the conduct of the PEARL I and II randomized controlled trials and for intermittent treatment after the observational PEA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d305f460dbe110f370fa6ff6f7b66a7
https://doi.org/10.1093/humrep/deac009